ORYZON to give updates on corporate progress in May

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in May.

Oryzon will participate at the Swiss Biotech Day, which will be held on May 2-3 in Basel (Switzerland). During this event, Dr. Carlos Buesa, Oryzon’s CEO, will give an update on corporate progress on May 2 at 16:00 CEST. Dr. Buesa will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about the Swiss Biotech Day

Oryzon will participate at the LSX World Congress, which will be held on May 10-11 in London (UK), where Dr. Buesa will give an update on corporate progress on May 10 at 15:15 local time. Dr. Buesa will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about the LSX World Congress

Oryzon will also participate at the BioEquity Europe conference, which will be held in Milan (Italy) and virtually on May 16-24. Dr. Buesa will present a corporate update and will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about the BioEquity Europe

Oryzon has been invited to attend the H.C. Wainwright Global Investment Conference, which will be held in Miami (USA) and virtually on May 23-26. Dr. Saikat Nandi, Oryzon’s Global Chief Business Officer, will give an update on corporate progress and will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info abou the H.C. Wainwright Global Investment Conference

Dr. Buesa will also participate at the PrecisionMed Expo & Summit, which will be held on May 24-25 in Dubai. Dr. Buesa will present a corporate update at the session on Genomic Profiling of Oncology Therapeutics on May 24 at 12:00 pm local time. Dr. Buesa will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about the PrecisionMed Expo & Summit

Finally, Dr. Jordi Xaus, Oryzon’s CSO, and Dr. Enric Rello, Oryzon’s CFO, will attend the Foro MedCap BME, the major event for European investors and listed medium/small-cap companies in Spain, which will be held on May 24-26 in Madrid (Spain). Dr. Xaus and Dr. Rello will hold one-to-one meetings with national investors. Click on link for more info about the Foro MedCap BME

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European leader in epigenetics. Oryzon has one of the strongest portfolios in the field, with two LSD1 inhibitors, iadademstat and vafidemstat, in Phase II clinical trials, and other pipeline assets directed against other epigenetic targets. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com

About Iadademstat

Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (see Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A FiM Phase I/IIa clinical trial with iadademstat in R/R AML patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi (see Salamero et al, J Clin Oncol, 2020, 38(36): 4260-4273. doi: 10.1200/JCO.19.03250). In an ongoing Phase IIa trial in elder 1L-AML patients (ALICE trial), iadademstat has shown encouraging safety and efficacy data in combination with azacitidine (see Salamero et al., ASH 2021 poster). Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), neuroendocrine tumors, medulloblastoma and others. In a Phase IIa trial in combination with platinum/etoposide in second line ED-SCLC patients (CLEPSIDRA trial), preliminary activity and safety results have been reported (see Navarro et al., ESMO 2018 poster). In total iadademstat has been dosed to more than 100 cancer patients in four clinical trials.

About Vafidemstat

Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer’s disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed two Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders (REIMAGINE) and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive clinical results reported in both. Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL trial in patients with Mild to Moderate AD, where a significant reduction of the inflammatory biomarker YKL40 has been observed after 6 and 12 months of treatment, and the pilot, small scale SATEEN trial in Relapse-Remitting and Secondary Progressive MS, where antiinflammatory activity has also been observed. Vafidemstat has also been tested in a Phase II in severe Covid-19 patients (ESCAPE) assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection, where it showed significant anti-inflammatory effects in severe Covid-19 patients. Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION). The company is also deploying a CNS precision medicine approach with vafidemstat in genetically-defined patient subpopulations of certain CNS disorders.